A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 Vaccines in Healthy Adults Between 18 Years and 55 Years of Age to Prevent COVID-19
A Phase 1, Randomized, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18-55 Years
Sponsor: ModernaTX, Inc.
Listed as NCT04813796, this PHASE1 trial focuses on SARS-CoV-2 and remains completed. Sponsored by ModernaTX, Inc., it has been updated 10 times since 2021, reflecting substantial change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Sep 2023 — Jul 2024 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Jul 2023 — Sep 2023 [monthly]
Active Not Recruiting PHASE1
-
Sep 2022 — Jul 2023 [monthly]
Active Not Recruiting PHASE1
▶ Show 5 earlier versions
-
Feb 2022 — Sep 2022 [monthly]
Active Not Recruiting PHASE1
-
Oct 2021 — Feb 2022 [monthly]
Active Not Recruiting PHASE1
-
Sep 2021 — Oct 2021 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Jun 2021 — Sep 2021 [monthly]
Recruiting PHASE1
-
Apr 2021 — Jun 2021 [monthly]
Recruiting PHASE1
First recorded
Mar 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- ModernaTX, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .